Provided by Tiger Fintech (Singapore) Pte. Ltd.

PepGen Inc.

1.45
+0.01000.69%
Post-market: 1.44-0.0100-0.69%19:29 EDT
Volume:105.04K
Turnover:150.83K
Market Cap:47.45M
PE:-0.46
High:1.46
Open:1.45
Low:1.39
Close:1.44
Loading ...

PEPG Lawsuit Alert! Class Action Lawsuit Against PepGen Inc.

TIPRANKS
·
17 Jul

PepGen Inc. Elects Directors at Annual Meeting

TIPRANKS
·
06 Jun

PepGen Inc. Conducted Annual Stockholders Meeting

Reuters
·
06 Jun

PepGen Inc.’s Strategic Shift to DM1 Program Earns Buy Rating Amid Promising Developments

TIPRANKS
·
30 May

PepGen Inc. Receives Buy Rating from Ananda Ghosh Due to Strategic Focus on Promising DM1 Program

TIPRANKS
·
30 May

PepGen Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
29 May

PepGen to discontinue DMD programs after PGN-EDO51 did not achieve target

TIPRANKS
·
29 May

PepGen Inc. Discontinues DMD Programs After Trial Results

TIPRANKS
·
29 May

PepGen Inc. Files Initial Beneficial Ownership Statement for Kasra Kasraian, Chief Technical Officer

Reuters
·
22 May

PepGen Inc. Appoints Kasra Kasraian, PhD, as New Chief Technology Officer

Reuters
·
20 May

PepGen Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
09 May

PepGen Inc expected to post a loss of 75 cents a share - Earnings Preview

Reuters
·
09 May

PepGen Q1 EPS $(0.92) Misses $(0.71) Estimate

Benzinga
·
08 May

BRIEF-PepGen Q1 EPS USD -0.92

Reuters
·
08 May

Press Release: PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Dow Jones
·
08 May

PepGen Inc. CEO Makes Bold Stock Purchase!

TIPRANKS
·
23 Apr

PepGen Inc.’s CEO Makes Bold Stock Purchase!

TIPRANKS
·
10 Apr

PepGen Inc. Expands Board with New Appointments

TIPRANKS
·
01 Apr

PepGen Announces Appointment of Two New Directors to its Board

Business Wire
·
01 Apr

PepGen Inc. Faces Clinical Trial Challenges and Competitive Pressures Leading to Sell Rating

TIPRANKS
·
05 Mar